ACHN Soars On PNH Data, ACAD Abuzz, ALDR On Track, Zealand To Debut On Nasdaq

Today’s Daily Dose brings you news about Achillion’s phase II trial results of ACH-4471 in paroxysmal nocturnal hemoglobinuria; ACADIA’s improving financials; Alder’s near-term catalysts; Navidea’s progress in its pipeline and Theravence’s anticipated milestones.

Read on…

Shares of Achillion Pharmaceuticals Inc. (ACHN) were up more than 27% in extended trading on Tuesday, following encouraging interim results from a phase II trial of ACH-4471 in patients with untreated paroxysmal nocturnal hemoglobinuria, or PNH.

According to the Company, interim trial results in four patients demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH. Patients with PNH have elevated levels of lactate dehydrogenase (LDH).

ACHN closed Tuesday’s trading at $4.01, up 1.01%. In after-hours, the stock was up 27.68% to $5.12.

ACADIA Pharmaceuticals Inc. (ACAD) reported a narrower loss for the second quarter of 2017 on higher net product sales.

For the three months ended June 30, 2017, the Company’s net loss shrunk to $67.4 million or $0.55 per share from $71.3 million or $0.63 per common share for the same period in 2016.

Net product sales of NUPLAZID, which was first made available for prescription starting in May 2016, were $30.5 million for the recent second quarter, up from $0.1 million in the comparable year-ago quarter.

ACAD closed Tuesday’s trading at $29.54, down 3.37%. In after-hours, the stock was up 13.07% to $33.40.

Aeterna Zentaris Inc.’s (AEZS) Strategic Review Committee, which has been formed to consider and evaluate various strategic and financing alternatives to maximize shareholder value, has engaged a consulting firm and a financial advisor to assist in its efforts.

Last month, the Company appointed Michael Ward as the Chief Executive Officer, replacing David Dodd.

AEZS closed Tuesday’s trading at $1.82, down 4.21%.

Alder BioPharmaceuticals Inc. (ALDR) is on track to complete enrollment in PROMISE 2, the second pivotal phase III study of Eptinezumab that focuses on chronic migraine, in the second half of 2017.

On June 27, 2017, Alder reported positive results from its phase III pivotal clinical trial of Eptinezumab for migraine prevention, dubbed PROMISE I.

Additional data from the Eptinezumab program are anticipated to be presented at the 18th Congress of the International Headache Society, to be held September 7-10, 2017.

ALDR closed Tuesday’s trading at $9.20, down 2.65%. In after-hours, the stock gained…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *